These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38606822)

  • 41. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.
    Zhong H; Sun S; Chen J; Wang Z; Zhao Y; Zhang G; Chen G; Zhou M; Zhou J; Du Y; Wu L; Xu Z; Mei X; Zhang W; He J; Cui J; Zhang Z; Luo H; Liu W; Sun M; Wu J; Shen Y; Zhang S; Yang N; Wang M; Lu J; Li K; Yao W; Sun Q; Yue H; Wang L; Ye S; Li B; Zhuang X; Pan Y; Zhang M; Shu Y; He Z; Pan L; Ling Y; Liu S; Zhang Q; Jiao S; Han B
    Lancet Respir Med; 2024 May; 12(5):355-365. PubMed ID: 38309287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
    Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
    Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
    Tanigawa T; Takeshima N; Ishikawa H; Nishio S; Usami T; Yamawaki T; Oishi T; Ihira K; Kato H; Goto M; Saito M; Taira Y; Yokoyama M; Shoji T; Kondo E; Mori A; Yokoi T; Iwasa-Inoue N; Hirashima Y; Nagasawa T; Takenaka M; Mikami M; Sugiyama T; Enomoto T
    Gynecol Oncol; 2022 Jun; 165(3):413-419. PubMed ID: 35487773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
    Suzuki K; Nagao S; Shibutani T; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
    Gynecol Oncol; 2019 Sep; 154(3):554-557. PubMed ID: 31285082
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
    J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
    Tewari KS; Colombo N; Monk BJ; Dubot C; Cáceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüs M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Toker S; Keefe SM; Lorusso D
    JAMA Oncol; 2024 Feb; 10(2):185-192. PubMed ID: 38095881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
    Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
    Kanda S; Goto K; Shiraishi H; Kubo E; Tanaka A; Utsumi H; Sunami K; Kitazono S; Mizugaki H; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Hozumi H; Tamura T
    Ann Oncol; 2016 Dec; 27(12):2242-2250. PubMed ID: 27765756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
    J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.
    Xia L; Wang J; Wang C; Zhang Q; Zhu J; Rao Q; Cheng H; Liu Z; Yin Y; Ai X; Gulina K; Zheng H; Luo X; Chang B; Li L; Liu H; Li Y; Lou G; Zhou Q; Zhu Y; Xiao Z; Tong J; Wang K; Chen J; Wang X; Song L; Wei Z; Ye Y; Zhu J; Wu X
    Int J Gynecol Cancer; 2023 Dec; 33(12):1861-1868. PubMed ID: 37875323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).
    Ishikawa M; Shibata T; Kataoka T; Takekuma M; Kobayashi H; Yaegashi N; Satoh T;
    Int J Gynecol Cancer; 2023 May; 33(5):692-700. PubMed ID: 36997229
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
    Oaknin A; Gladieff L; Martínez-García J; Villacampa G; Takekuma M; De Giorgi U; Lindemann K; Woelber L; Colombo N; Duska L; Leary A; Godoy-Ortiz A; Nishio S; Angelergues A; Rubio MJ; Fariñas-Madrid L; Yamaguchi S; Lorusso D; Ray-Coquard I; Manso L; Joly F; Alarcón J; Follana P; Romero I; Lebreton C; Pérez-Fidalgo JA; Yunokawa M; Dahlstrand H; D'Hondt V; Randall LM;
    Lancet; 2024 Jan; 403(10421):31-43. PubMed ID: 38048793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
    Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
    N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
    Kuo DY; Blank SV; Christos PJ; Kim M; Caputo TA; Pothuri B; Hershman D; Goldman N; Ivy PS; Runowicz CD; Muggia F; Goldberg GL; Einstein MH
    Gynecol Oncol; 2010 Mar; 116(3):442-6. PubMed ID: 19931137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
    Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
    Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
    Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
    Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.